StockData
Sigyn Therapeutics, Inc. logo

Sigyn Therapeutics, Inc. (SIGY) stock

SIGYOTCSurgical & Medical Instruments & ApparatusFiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2025, quý kết thúc ngày Sep 30, 2025Last filing: 10-Q on Nov 14, 2025Score 0/30
$0.03+0.00 (0.00%)

Close on Oct 19, 2026Market cap $48.16KP/E –Yield –

Key statistics

Valuation at the latest close; fundamentals over fiscal , balances at Sep 30, 2025

Valuation

Market cap
$48.16K
P/E ratio
–
Price to sales
–
Price to book
–
Dividend yield
–
Free cash flow yield
–

Fundamentals

Net income
-$3.22M
EPS, diluted
-$2.01
Book value per share
-$3.69
Diluted shares
2M

Trading

Previous close
$0.03
Open
$0.03
Day's range
$0.03 – $0.03
Volume
3,109
Average volume (20 days)
14,264

Market cap history

Month-end market cap since 2021, using shares outstanding reported at the time

Total return vs. the S&P 500

Price change plus reinvested dividends, to the close on Oct 19, 2026. The S&P 500 is measured by the SPY fund.

PeriodSIGYS&P 500DifferenceSIGY per yearS&P 500 per year
1 month-13.8%+0.6%−14.4 pts
3 months-25.0%+3.4%−28.4 pts
Year to date-98.2%+13.3%−111.5 pts
1 year-98.5%+16.6%−115.1 pts
3 years-99.7%+86.4%−186.0 pts-84.9%+23.1%
5 years-99.8%+81.9%−181.7 pts-72.3%+12.7%

Twelve years at a glance

Fiscal years 2013 to 2024 and trailing twelve months, USD

Revenue

–

Gross profit

–

Operating income

-$1.88M

Net income

-$3.22M

EPS, diluted

-$2.01

Free cash flow

–
Reported periodTrailing twelve months

Press releases

Releases Sigyn Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K

All press releases and earnings

About Sigyn Therapeutics

Surgical & Medical Instruments & Apparatus

Sigyn Therapeutics, Inc. is a medical device company that develops extracorporeal blood purification technologies to address cancer and infectious disease disorders. The company’s portfolio includes platforms designed to enhance cancer treatments, including the ImmunePrep platform to optimize immunotherapeutic antibody delivery, ChemoPrep to improve chemotherapy delivery, and ChemoPure to lower treatment toxicity by removing off-target chemotherapy. Its lead candidate, Sigyn Therapy, is a single-use disposable device designed to extract pathogens, bacterial toxins, hepatic toxins, and inflammatory cytokines from blood plasma, targeting conditions such as viral infections, antibiotic-resistant bacteria, endotoxemia, and sepsis.

Company profile, executives and history

Sigyn Therapeutics stock: common questions

What is Sigyn Therapeutics's stock price?

SIGY closed at $0.03 on Oct 19, 2026, up 0.00% on the day.

What is Sigyn Therapeutics's market cap?

Sigyn Therapeutics was worth $48.16K at the close on Oct 19, 2026: the share price times the diluted shares outstanding.

What is SIGY's P/E ratio?

Sigyn Therapeutics lost money over the twelve months to Sep 30, 2025 (diluted EPS -$2.01), so it has no meaningful P/E ratio.

Does Sigyn Therapeutics pay a dividend?

No. Sigyn Therapeutics has not paid a cash dividend over the last twelve months.

How has SIGY stock performed over the past year?

Including dividends, SIGY returned -98.5% over the past year, against +16.6% for the S&P 500.

Who are Sigyn Therapeutics's competitors?

Companies most similar to Sigyn Therapeutics by business, industry and size include CTSO, ICU, RNXT, CERS, BJDX.

See a number that looks wrong?